Partner Headlines - TEVA

  1. Teva Announces U.S. Availability of ZECUITY® (sumatriptan iontophoretic ...

    Benzinga
  2. Mylan Confirms USPTO Institutes Inter Partes Review Proceedings ...

    Benzinga
  3. Allergan Modestly Tops Views

    IBD
  4. Allergan Q2 Beats, But Generics Sale Clouds Outlook

    IBD
  5. Israeli Tech Startups Attract Record Funding In Q2

    IBD
  6. 5 Top Medical Stocks Reporting Earnings This Week

    IBD
  7. Teva's Deal-Making Spurs Inflows To Israel ETFs

    Benzinga
  8. Benzinga's Top Upgrades

    Benzinga
  9. IBD 50: 10 Top Stocks Reporting Earnings This Week

    IBD
  10. These 4 Foreign Drug Stocks Have Broken Out Recently

    IBD
  11. 5 Hot Drug Stocks Top IBD's Big Cap Leaders Screen

    IBD
  12. Wakefulness Drug Xyrem Keeps Jazz Pharmaceuticals Up

    IBD
  13. Amgen Stock Clears Buy Point Ahead Of Earnings

    IBD
  14. Stocks In Rebound Mode; Icon, Cadence Break Out

    IBD
  15. Can Health Care Sector Continue its Incredible Run?

    FoxBusiness
  16. Weekly 52-Week Highs Highlight: GIS, AAP, BCR, TEVA

    GuruFocus
  17. Benzinga's Top Upgrades

    Benzinga
  18. Teva Announces European Medicines Agency (EMA) Confirms Successful ...

    Benzinga
  19. Teva Prefers Allergan Unit

    IBD
  20. Benzinga's M&A Chatter for Monday July 27, 2015

    Benzinga
  21. Stocks Fall For Fifth Straight Session On China Woes

    IBD
  22. Allergan CEO: Teva Made A 'Compelling Offer' We Couldn't Refuse

    Benzinga
  23. Market Update: Monday's Top 10 Volume Movers

    Benzinga
  24. Stocks Mired In Red, Hurt By China Weakness; Boot Barn Bounces

    IBD
  25. Market Update: Monday's Mid-Day Movers, China's Stock Market ...

    Benzinga
  26. Stocks In The Red But Off Lows As Shanghai, Europe Weigh

    IBD
  27. Teva Drops Mylan Chase To Buy Allergan Generics Unit

    IBD
  28. Benzinga's Volume Movers

    Benzinga
  29. Teva Confirms Allergan Generics Buy, Drops Mylan Bid

    IBD
  30. U.S. Stocks On Track For Weak Open As Chinese Stocks Sink

    IBD
  31. UPDATE: Mylan Issues Comment on Teva Deal to Buy Allergan's Generic ...

    Benzinga
  32. UPDATE: Teva Withdraws Proposal to Acquire Mylan

    Benzinga
  33. UPDATE: Teva to Acquire Allergan Generics for $40.5 B

    Benzinga
  34. Benzinga's Weekend M&A Chatter

    Benzinga
  35. Teva To Buy Allergan's Generic Drug Unit, Unit Worth ~$45B, Deal ...

    Benzinga
  36. Biotech IPO Boom Gaining Thrust With NantKwest Debut

    IBD
  37. Morning-after pill use increases

    IBD
  38. Novartis' Mixed Q2: Sandoz Booms, Alcon Struggles

    IBD
  39. Rapid7 IPO Pops 52%; Investors Hungry For Blue Buffalo

    IBD
  40. Painkiller Abuse Drives Drugmakers To Innovate

    IBD
  41. Celgene Hits High As Street Applauds Receptos Buyout

    IBD
  42. Teva-Mylan merger opposed

    IBD
  43. Benzinga's Top Initiations

    Benzinga
  44. Medicines Co., Eagle Pharma Up On Analyst Actions

    IBD
  45. Momenta Pharma

    IBD
  46. Momenta Downgraded After Stock Price Doubles

    IBD
  47. Teva-Xenon Arthritis Pain Drug Fails Midstage Trial

    IBD
  48. Wednesday's Mid-Day Movers: Chubb, Rock Creed, RADA Win; Peabody ...

    Benzinga
  49. Unusual Covered Call Opportunity Teva Pharmaceuticals

    Benzinga
  50. Alder Bio Up As Credit Suisse Lauds Migraine Drug

    IBD
  51. New America's IPO Stock Winners: Fitbit, Arista

    IBD
  52. ObamaCare Enables Health Insurer Merger Mania

    IBD
  53. Paul Tudor Jones Buys Stakes in ADP and Visa

    GuruFocus
  54. Teva Migraine Drug Succeeds In Midstage Trial

    IBD
  55. Teva Migraine Drug Succeeds In Midstage Trial

    IBD
  56. Teva to Present New Findings at the American Headache Society ...

    Benzinga
  57. How High Can Eagle Pharmaceuticals Fly On Teva Deal?

    IBD
  58. Teva's Mylan bid hits snag

    IBD
  59. Teva's Auspex Buyout Pays, But Mylan Bid Hits Snag

    IBD
  60. Teva Advances Pipeline of Movement Disorder Assets with Announcement ...

    Benzinga
  61. Top Biotech Stock Files For New Drug, In Buy Range

    IBD
  62. Activist Hedge Fund Manager Has Strong Focus on Health Care Stocks

    GuruFocus
  63. New Migraine Drugs Could Ease Investors' Headaches

    IBD
  64. Benzinga's M&A Chatter for Tuesday June 9, 2015

    Benzinga
  65. Leon Cooperman's Top Holdings Look Attractive

    GuruFocus
  66. Teva Pharmaceuticals

    IBD
  67. 6-K from Teva Pharma Shows Letter from CEO Vigodman, Chair Peterburg ...

    Benzinga
  68. Mobileye Hangs Just Below Buy Point In Deep Cup Base

    IBD
  69. Perrigo buys Glaxo OTC drugs

    IBD
  70. Will Perrigo's Glaxo Buy Make It Too Pricey?

    IBD
  71. Mylan Sends Letter to Teva CEO

    Benzinga
  72. Teva Announces Exclusive Launch of Generic Actonel Tablets in ...

    Benzinga
  73. Teva to pay $1.2 bil to settle

    IBD
  74. Regeneron, Lannett Among The 4 Top-Rated Drug Stocks

    IBD
  75. Benzinga's M&A Chatter for Wednesday May 27, 2015

    Benzinga
  76. TEVA PHARMA

    IBD
  77. Actavis Stock - A Must Have For Long-Term Investors

    GuruFocus
  78. Big Pharma Companies Are Betting On Regenerative Medicine - Should ...

    GuruFocus
  79. Stanley Druckenmiller's Top 5 New Stocks

    GuruFocus
  80. Endo International Acquires Par Pharmaceuticals For $8 Billion

    GuruFocus
  81. Endo Buying Par Pharma To Become Top Generics Player

    IBD
  82. IPO Stock Watch: Alder Soars On Migraine Drug Results

    IBD
  83. U.S. Loves Europe As Pharma, Energy Boost M&A

    IBD
  84. Actavis Offers Post-Allergan Guidance; Ligand Jumps

    IBD
  85. Actavis Q1 Beats Estimates, Includes Allergan In 2015 Guidance

    IBD
  86. Benzinga's Weekend M&A Chatter

    Benzinga
  87. Report: Mylan Might See Higher Bid From Teva

    Benzinga
  88. Jim Chanos, Kyle Bass Rip Oil And Pharma At SALT 2015

    Benzinga
  89. Alexion's $8.4 Billion Synageva Buyout Spooks Street

    IBD
  90. Leading Stock Mallinckrodt Delivers Strong Results As Base Forms

    IBD
  91. Mylan Q1 Mixed; Abiomed, Mallinckrodt, Zoetis Beat

    IBD
  92. Report Sees 'Cognitive Dissonance' In Mylan's Internal Price ...

    Benzinga
  93. M&A Fever Grips Drugmakers

    IBD
  94. Is The Drug Industry's Wedding Dance Nearly Finished?

    IBD
  95. Gilead's Strong Profit Tops Mixed Drug maker Reports

    IBD
  96. Teva tops as it tries for Mylan

    IBD
  97. Teva, Celgene, Novo Nordisk, Shire Report Q1 Earnings

    IBD
  98. Teva Beats Q1 Estimates, Raises Full-Year Forecast

    Benzinga
  99. Mylan Raises Perrigo Bid, But Perrigo Still Says No

    IBD
  100. Benzinga's M&A Chatter for Monday April 27, 2015

    Benzinga
Trading Center
×

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!